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has been implicated in the pathogenesis of sepsis. We recently
demonstrated that ET-1 plays an important role in the development
of ALI in a rat model of sepsis. As an extension of recent study, in this
investigation we investigated whether landiolol hydrochloride, an
ultra- short-acting β-blocker, can play an important role in
ameliorating LPS-induced ALI through the normalization of ET-1.
Male Wistar rats at 8 weeks of age were administered with either
saline or lipopolysaccharide (LPS) for 3 h and some LPS-administered
rats were continuously treated with landiolol for 3 h. The features of
acute lung injury were observed at sepsis model. At 3 h after LPS
administration, both circulatory and pulmonary TNF-α levels
increased and PaO2 signiﬁcantly decreased LPS administration. LPS
induced a time-dependent expression of ET-1 in the lungs compared
to control, peaking and increasing by 3 fold at 6 h after induction of
endotoxemia, whereas levels of ET (B) receptor, which has
vasodilating effects, were remarkably down regulated time-depen-
dently. We conclude that time-dependent increase of ET-1 and ET
(A) receptor with the down regulation of ET (B) receptor may play a
role in the pathogenesis of acute lung injury in endotoxemia. Finally,
treatment of LPS-administered rats with landiolol for 3 h failed to
normalize the upregulated pulmonary ET-1 and TNF-α levels.
Another study found that landiolol can ameliorate ALI in LPS-induced
sepsis model. These data taken together, led us to conclude that
landiolol mediated ALI improvement in sepsis does not involve
pulmonary ET system.
doi:10.1016/j.lfs.2014.01.013
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Background: Expression of transient receptor potential subfamily C
(TRPC) 6, receptor-operatedCa2+channels, is increased in hypertrophic
and failing hearts. TRPC6 has been shown to be a positive regulator of
calcineurin-NFAT signaling that drives pathological cardiac remodeling.
In this study we examined the effect of TRPC inhibition on the
pathological cardiac hypertrophy. Methods and results: In cultured
neonatal rat ventricular myocytes, overexpression of TRPC6 increased
basal and ET-1 inducedNFAT-dependent RCAN1promoter activity. BTP2,
a selective TRPC channel blocker, signiﬁcantly and dose-dependently
inhibited activation of the RCAN1 promoter, and attenuated hypertro-
phic response of cultured cardiac myocytes. Knocking-down of TRPC6
and 3 using siRNAs signiﬁcantly inhibited ET-1- or Ang II-induced
increases in Ca2+ oscillation, and knocking down either TRPC6 or 3 had a
similar effect. In model mice lacking GC-A, which is a common receptor
for atrial and brain natriuretic peptides, the expression of TRPC6 and
RCAN1 was increased and BTP2 signiﬁcantly attenuated the cardiac
hypertrophy observed inGC-AKOmicewithout affecting blood pressure.
BTP2 also inhibited AngII-induced cardiac hypertrophy in mice. Com-
patible with the notion that TRPC6 and 3 form heteromultimeric cation
channels, Pyrazole-3, a selective TRPC3 blocker, which can inhibit the ion
channel activity of TRPC3/6 hetero-complex, also signiﬁcantly inhibited
Ang-II induced cardiac hypertrophy in mice. Conclusions: Blockade of
TRPC6 could be a novel therapeutic strategy for preventing pathological
cardiac remodeling.
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Landiolol, an ultra-short-acting and highly cardioselective beta-1
blocker, has become useful for various medical problems. Recent studies
have demonstrated that co-treatment with landiolol protects against
acute lung injury and cardiac dysfunction in a rat model of lipopolysac-
charide (LPS)-induced systemic inﬂammationwhichwas associatedwith
a signiﬁcant reduction in serum levels of the inﬂammation mediator
HMGB-1 and histological lung damage. Endothelin (ET)-1, a potent
vasoconstrictor, has been implicated in the pathogenesis of sepsis and
sepsis-induced multiple organ dysfunction syndrome. In the current
study, we investigated whether landiolol hydrochloride can play an
important role in ameliorating the LPS-induced altered cardiac ET system
in a rat model of endotoxemia. Male Wistar rats at 8 weeks of age
were administered LPS for 3 h and some LPS-administered rats were
continuously treated with landiolol for three hours. At 3 h after LPS
administration, circulatory TNF-alpha level was highly increased. Blood
lactate concentration and percentage of fractional shortening of heart
have also signiﬁcantly increased after LPS administration. In addition, LPS
induced a signiﬁcant upregulated expression of various components of
ET-1 system in the cardiac tissues compared to control. Finally, treatment
of LPS-administered ratswith landiolol for 3 h potentially normalized the
increased blood lactate level, cardiac functional compensatory events
without an effect on plasma TNF-alpha and ET-1 levels. Most strikingly,
landiolol treatment has greatly normalized the various components of
ET-1 system in endotoxemic heart. These data taken together, led us to
conclude that landiolol may be cardio protective in endotoxemia
normalizing the vasoactive peptide like endothelin without altering the
circulatory level of potential inﬂammatory cytokine like TNF-alpha.
doi:10.1016/j.lfs.2014.01.015
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Growing body of evidences state the cardiovascular beneﬁt of
ﬁsh oil including eicosapentaenoic acid (EPA) in humans and experi-
mental animals, but the effect of EPA on endothelin (ET)-1-induced
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